KOPRAN vs THEMISMED: Stock Comparison

KOPRAN vs THEMIS MEDICAREUpdated 4 Sept 26, 4:08 PM ISTNSE & company filings

THEMIS MEDICARE is the larger company by market capitalisation. KOPRAN shows a higher ROE, a higher dividend yield and lower leverage, while THEMIS MEDICARE shows a lower P/E and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

KOPRAN leads 8; THEMISMED leads 5 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

KOPRANTHEMISMED

Valuation lens

What price are you paying?

Market CapContext only
₹1,120 Cr
₹1,124 Cr
P/E RatioTHEMISMED has the lower reading
37.34x
27.4x
P/B RatioKOPRAN has the lower reading
1.76x
2.75x
EPSTHEMISMED has the higher reading
₹1.39
₹2.67
Book ValueContext only
₹109.82
₹43.28
Dividend YieldKOPRAN has the higher reading
2.76%
0.4%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
THEMISMED is the larger company
₹1,124 Cr vs ₹1,120 Cr
P/E Ratio
THEMISMED has a lower P/E
27.4x vs 37.34x
P/B Ratio
KOPRAN has a lower P/B
1.76x vs 2.75x
EPS
THEMISMED has higher earnings per share
₹2.67 vs ₹1.39
Dividend Yield
KOPRAN has a higher dividend yield
2.76% vs 0.4%
Revenue Growth (TTM YoY)
THEMISMED has faster revenue growth
6.7% vs -3.66%
EPS Growth (TTM YoY)
THEMISMED has faster EPS growth
0% vs -71.88%
Qtr Sales Growth
THEMISMED has stronger quarterly sales growth
0% vs -59.25%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricKOPRANTHEMISMED
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricKOPRANTHEMISMED
Live Price₹232.54₹120.42
Day Change0.13%-3.56%
Volume6.61 L1.59 L
52-Week High₹239.6₹148
52-Week Low₹107₹64.95
Distance from 52W High-2.95%-18.64%

Valuation

MetricKOPRANTHEMISMED
Market Cap₹1,120 Cr₹1,124 Cr
P/E Ratio37.34x27.4x
P/B Ratio1.76x2.75x
EPS₹1.39₹2.67
Book Value₹109.82₹43.28
Dividend Yield2.76%0.4%

Growth

MetricKOPRANTHEMISMED
Revenue Growth (TTM YoY)-3.66%6.7%
EPS Growth (TTM YoY)-71.88%0%
Qtr Sales Growth-59.25%0%
Qtr Profit Growth0.33%-14.36%

Profitability & Leverage

MetricKOPRANTHEMISMED
ROE4.85%-4.71%
ROCE4.89%-0.63%
Net Margin3.78%0.33%
Operating Margin6.58%-0.79%
Debt to Equity0.29x0.33x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricKOPRANTHEMISMED
Promoter Holding44.42%57.5%
FII Holding0.51% 0.06 pp0.01% 0.1 pp
DII Holding0%0.01%
Public Holding55.06% 0.06 pp32.87% 0.09 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: KOPRAN and THEMIS MEDICARE.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.